Locally Advanced Pancreatic Adenocarcinoma Clinical Trial
Official title:
PREOPERATIVE CHEMOTHERAPY DOES NOT ADVERSELY AFFECT SHORT-TERM OUTCOME AFTER PANCREATIC RESECTION.
No comparative trial investigating the effect of preoperative chemotherapy for locally advanced pancreatic cancer on short-term postoperative outcome has been published so far. The aim of the present study is to assess the potential impact of preoperative chemotherapy on short-term postoperative outcome after pancreatic resection in a case-matched series of cancer patients.
Between 2003 and 2011, patients with locally advanced (stage III) pancreatic cancer who were treated with preoperative chemotherapy (PCHT) underwent surgical resection. Each patient was matched with the closest two patients with pancreatic cancer ( control group ) selected from our prospective electronic database who met the following match criteria: age (+/- 3 years), gender, ASA score, type of resection, pancreatic duct diameter (+/- 1 mm), and tumour size (+/- 5 mm). ;
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05679674 -
Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer
|
N/A | |
| Recruiting |
NCT04617821 -
AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer
|
Phase 3 | |
| Completed |
NCT03673137 -
Phase II/III of Randomized Controlled Clinical Research on IRE Synchronous Chemotherapy for LAPC
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04652206 -
Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients.
|
Phase 1/Phase 2 | |
| Completed |
NCT02394535 -
Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT06381154 -
Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advance or Metastatic Pancreatic Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT06399172 -
OncoSil Pancreatic Cancer Post-marketing Clinical Registry - Italy
|
||
| Withdrawn |
NCT03536182 -
Trial of Carbon Ion Versus Photon Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer
|
Phase 3 | |
| Recruiting |
NCT04395469 -
FAZA PET/MRI Pancreas
|
N/A | |
| Active, not recruiting |
NCT01585805 -
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT05607953 -
Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma
|
Phase 1 | |
| Active, not recruiting |
NCT03269526 -
BATs Treatment for Pancreatic Cancer, Phase Ib/II
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05524090 -
PREOPANC-4 Implementation Program for Locally Advanced Pancreatic Cancer
|
||
| Completed |
NCT01342224 -
Immunochemoradiotherapy in Patients With Pancreatic Cancer
|
Phase 1 | |
| Recruiting |
NCT04172532 -
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to Radiation Therapy for Localized Pancreatic Cancer
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04423731 -
Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer
|
||
| Not yet recruiting |
NCT06272162 -
Locally Advanced Pancreatic Cancer After Systemic Therapy: Ablative MR-guided Radiotherapy
|
N/A | |
| Active, not recruiting |
NCT00669734 -
Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery
|
Phase 1 | |
| Recruiting |
NCT04665947 -
First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer
|
Early Phase 1 | |
| Recruiting |
NCT04570943 -
Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
|
Phase 2 |